Business Context and Reporting Period
This Form 8-K filing by Pacific Biosciences of California, Inc. covers the period ending October 30, 2017. The report primarily addresses a significant executive appointment and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $1.00 annually.
- Target Bonus: 50% of base salary.
- Equity Grant: Stock option to purchase 375,000 shares, vesting over four years.
Material Changes
On October 30, 2017, the Board appointed Kathy Ordoñez as Chief Commercial Officer and Executive Vice President. Concurrently, she resigned from her roles as chair and member of the Corporate Governance and Nominating Committee and as a member of the Compensation Committee. She remains a Class III director and chair of the Science and Technology Committee.
Outlook, Risks, and Unusual Items
Compensatory Arrangements: Ms. Ordoñez entered into a Change of Control and Severance Agreement. If terminated without cause or for good reason within 12 months of a change in control, she is entitled to six months of base salary and immediate acceleration of 100% of unvested equity awards.
Management Commentary: The appointment leverages Ms. Ordoñez's over 30 years of experience in life sciences and diagnostics, including prior leadership roles at RainDance Technologies, Quest Diagnostics, Celera, and Hoffmann-La Roche.
Investor Verification Checklist
- Verify the final Board approval of the 375,000 share stock option grant.
- Review the full text of the Change of Control and Severance Agreement for specific definitions of "good reason" and "change in control."
- Confirm the impact of the $1.00 base salary structure on total executive compensation reporting.
- Check subsequent filings for any updates to the vesting schedule or equity plan amendments.